ライフサイエンスコーパス: Roche

1 rmed using the Linear Array genotyping test (Roche).

2 M was sequenced (RNA-Seq) using GS FLX+ (454/Roche).

3 16S 454 FLX titanium series pyrosequencing (Roche).

4 ared with laboratory pVL assessment (TaqMan, Roche).

5 French Ministry of Health and Hoffmann-La Roche.

6 ma Research Trust, Lymphoma Association, and Roche.

7 h Network, the Medical Research Council, and Roche.

8 t protease inhibitor (saquinavir, Hoffman La-Roche, 1995) and two decades since the approval of the f

9 nomes exon pilot project generated using the Roche 454 and Illumina sequencing platforms, and were ab

10 Users can turn a collection of reads (from Roche 454 chemistry) or assembled contigs (from any sequ

11 SR in comparison to Roche gsAssembler on two Roche 454 GS FLX runs.

12 us strain genome sequencing was performed on Roche 454 GS FLX Titanium, then AB SOLiD instruments.

13 umina (Genome Analyzer, HiSeq, MiSeq, .etc), Roche 454 GS System, Applied Biosystems SOLiD System, He

14 ected to high-throughput pyrosequencing on a Roche 454 GS-FLX platform.

15 Here we used Roche 454 next-generation pyrosequencing of sedimentary

16 Different sequencing method (Roche 454 or Illumina sequencing) did not affect the acc

17 We used capillary electrophoresis and Roche 454 pyrosequencing to determine the number of repe

18 Culture-independent high-density Roche 454 pyrosequencing was used to survey the distal g

19 ria, as compared with standard single-region Roche 454 Pyrosequencing.

20 Roche 454 sequencing data were assembled into c. 22,000

21 Using Roche 454 sequencing of reverse transcription polymerase

22 rom selected multiplex T1D families, we used Roche 454 sequencing with Conexio Genomics ASSIGN ATF 45

23 s PGM and Proton, Pacific Biosciences RS and Roche 454).

24 n sequencing platforms (SOLiD, Illumina, and Roche 454).

25 resulting sample with both Illumina GAII and Roche 454, and obtained data with equally high specifici

26 DNA sequencing data from the Roche 454, Illumina/Solexa, and ABI SOLiD platforms typi

27 The amplicons were sequenced by Roche 454, the genomes assembled by de novo assembly, an

28 m detection, and apply them to data from the Roche (454) Genome Sequencer 20.

29 Here, we have used Roche-454 16S rRNA gene pyrosequencing to longitudinally

30 bidopsis thaliana), is being assembled using Roche-454 sequencing.

31 Yoka poxvirus genome using a combination of Roche/454 and Illumina next-generation sequencing techno

32 inGAP can be applied to the mapping of both Roche/454 and Illumina reads with no restriction of read

33 hetic (yet realistic) datasets, based on the Roche/454 and PacBio RS II sequencing technologies.

34 detection assay is made compatible with the Roche/454 Genome Sequencer FLX Titanium next-generation

35 Using Roche/454 GS FLX instrument, we acquired 7.6 million seq

36 using the long-read pyrosequencing platform (Roche/454 GS FLX Titanium) in high coverage.

37 s up to 4x faster than HapCol in the case of Roche/454 instances and up to 20x faster when compared o

38 ients infected with subtype 1a and performed Roche/454 pyrosequencing across the coding region.

39 I typing was performed on cellular RNA using Roche/454 pyrosequencing.

40 th high sensitivity and specificity, in both Roche/454 sequencing of individuals and deep Illumina/So

41 Roche/454 sequencing of the adult transcriptome produced

42 We compare sequencing platforms from Roche/454(GS FLX), Illumina/HiSeq (HiSeq 2000), and Life

43 IV reverse transcriptase (RT) was performed (Roche/454), and the sequences were screened for nucleosi

44 oughput and relatively short read lengths of Roche/454, Illumina/Solexa, and other platforms have spu

45 versity of Basel, University Hospital Basel, Roche, Abbott, and Singulex.

46 Chiral Roche aldehyde is obtained with 97% ee from the hydrofor

47 y (hs) cTn assays (hs-cTnI, Abbott; hs-cTnT, Roche) among 2300 consecutive patients with suspected AM

48 .3% for the Roche Cobas assay, 94.5% for the Roche Amplicor assay, 93.0% for the Biocentric assay, an

49 comparing the performances of ddPCR and the Roche Amplicor CT/NG test.

50 These assays were compared to the Roche Amplicor HIV-1 Monitor Test, v1.5, using panels of

51 -1 subtype detection, and correlation to the Roche Amplicor HIV-1 monitor test, version 1.5 (Amplicor

52 [RT-PCR]), Roche TaqMan RUO (Roche RT-PCR), Roche Amplicor Monitor HCV 2.0 (Roche Monitor), and Baye

53 ma viral loads using the Abbott test and the Roche Amplicor Monitor test showed a mean difference of

54 three FDA-approved platforms: UltraSensitive Roche Amplicor Monitor, v1.5 (Monitor), the Abbott RealT

55 s tested individually and in pools using the Roche Amplicor PCR for C. trachomatis and N. gonorrhoeae

56 obeTec SDA, Gen-Probe Aptima Combo2 TMA, and Roche Amplicor PCR) for detection of C. trachomatis and

57 nson ProbeTec, Gen-Probe Aptima Combo 2, and Roche Amplicor tests to detect Chlamydia trachomatis and

58 virus type 1 (HIV-1) plasma RNA levels using Roche AMPLICOR version 1.5 (HIV RNA) is an integral part

59 tion [PCR] results for C. trachomatis DNA by Roche Amplicor) and 25 true-negative specimens (direct o

60 Concordance with the Roche Amplicor, BDProbeTec ET, and Gen-Probe APTIMA Comb

61 ted a sensitivity of 100% (46/46), while the Roche analyte-specific reagents (ASR) and LDT showed sen

62 a laboratory-developed test (LC CMV) (using Roche analyte-specific reagents [ASR] on the LightCycler

63 e analytical performance of READ platform to Roche analyzer as a prospective clinical validation meth

64 nd ribavirin had HCV RNA <LLOQ at EOT by the Roche and Abbott assays, but only 38 achieved SVR12 (PPV

65 F Hoffmann-La Roche and Chugai Pharmaceutical.

66 solid form screens conducted at Hoffmann-La Roche and Eli Lilly and Company over the course of 8+ an

67 th; with drug supply provided by Hoffmann-La Roche and Genentech.

68 gle-nucleotide polymorphisms (SNPs) from the Roche and Genomic Institute of the Novartis Research Fou

69 RESTO has been tested on data generated from Roche and Illumina platforms.

70 trons on real RNA-seq data sets from PacBio, Roche and Illumina runs, and on six benchmarks, and comp

71 hilst at least one in two compounds from the Roche and Lilly set display polymorphism with a higher e

72 as found in VitaCyte product followed by the Roche and Serva/Nordmark products.

73 Roche and the National Institute for Health Research thr

74 ining data generated from 454 Life Sciences (Roche) and Illumina (formerly known as Solexa sequencing

75 Using 454 Life Sciences (Roche) and Illumina sequencing (formerly Solexa sequenci

76 was accomplished using a combination of 454 (Roche) and Illumina sequencing and community-based fundi

77 e sequences for 19 Typhi isolates using 454 (Roche) and Solexa (Illumina) technologies.

78 say (96.2%, 86.0%, and 73.9% for the Abbott, Roche, and BD tests, respectively) in sample types forma

79 was 89.1%, 82.1%, and 59.2% for the Abbott, Roche, and BD tests, respectively.

80 or Infectious Disease Research), Hoffmann-La Roche, and Gilead Sciences.

81 iiV Healthcare, Merck, Pfizer, F Hoffmann-La Roche, and Janssen Pharmaceuticals.

82 Ingelheim, Janssen, Merck, ViiV Healthcare, Roche, and Monogram Biosciences (LabCorp).

83 tau measured using assays from Quanterix and Roche, and the specificity of NT1 for AD versus a nonspe

84 real-time PCR method using the LightCycler (Roche Applied Science, Indianapolis, IN) was compared to

85 ssing with the MagNA Pure LC instrument (MP; Roche Applied Science, Indianapolis, IN) were evaluated

86 The Roche ASR in combination with the High Pure system (Roch

87 Roche ASR-HP underestimated HCV RNA for genotypes 3 and

88 SR in combination with the High Pure system (Roche ASR-HP) showed a sensitivity of 1.4 log(10) IU/ml

89 on (R(2) = 0.79) and agreement were poor for Roche ASR-HP, with bias relative to concentration and ge

90 trated increased sensitivity compared to the Roche ASR.

91 -9451, 100% (59/59) had HCV RNA <LLOQ by the Roche assay and 1 relapsed (PPV, 98%).

92 the Abbot assay was more sensitive than the Roche assay for both C. trachomatis and N. gonorrhoeae.

93 assay and those detected by the Siemens and Roche assays (92.0% and 88% correlation coefficient of t

94 Tau was measured using Quanterix and Roche assays in baseline subjects with SCD and MCI.

95 near and correlate well with the established Roche assays used in clinical practice.

96 tau, but not tau measured using Quanterix or Roche assays, is elevated in subjects who progress to AD

97 ed by the Basel S-gene and WHO-based E-gene (Roche) assays in parallel using the Basel N-gene assay f

98 Basel, Switzerland) and daclizumab (Zenapax; Roche, Basel, Switzerland) combined (relative risk, 0.54

99 h factor (VEGF) agent ranibizumab (Lucentis; Roche, Basel, Switzerland) compared with ranibizumab mon

100 ion, chlorination, and amination of the homo-Roche building blocks was performed to demonstrate that

101 The modified Roche CAP/CTM assay provides a convenient, standardized

102 says and 0.99 (95% CI, 0.96 to 1.00) for the Roche CAP/CTM Qual assay.

103 al [CI], 0.95 to 1.00) for the AmpliSens and Roche CAP/CTM Qual assays and 0.96 (95% CI, 0.90 to 0.98

104 mmended threshold of >1,000 copies/ml on the Roche CAP/CTM system.

105 tem cytomegalovirus (CMV) DNA (version 2.0), Roche CMV UL54 analyte-specific reagent, and QIAGEN Real

106 n susceptibility using residual DNA from the Roche Cobas 4800 CT/NG assay.

107 mydia trachomatis and Neisseria gonorrhoeae (Roche cobas 4800), a fully automated system, was compare

108 logic Panther Fusion, DiaSorin Simplexa, and Roche Cobas 6800 failed to detect positive specimens onl

109 asured via indirect potentiometry, using the Roche Cobas 8000 routine chemistry analyzer.

110 Roche COBAS Amplicor and Bayer VERSANT HCV RNA qualitati

111 Results were compared to those of the Roche Cobas Amplicor CT/NG assay.

112 polymerase chain reaction (PCR)-based assay (Roche COBAS Amplicor HCV Test, v.

113 at the amplicon generated by the widely used Roche COBAS Amplicor Hepatitis C Virus Test, version 2.0

114 The Roche COBAS AMPLICOR human immunodeficiency virus type 1

115 DNA strand displacement assay (SDA), and the Roche Cobas Amplicor PCR was defined by using a rotating

116 me PCR assay by comparison with the existing Roche COBAS AmpliPrep/AMPLICOR MONITOR conventional PCR

117 ed with the AmpliSens DNA-HIV-FRT assay, the Roche COBAS AmpliPrep/COBAS TaqMan (CAP/CTM) HIV-1 Qual

118 We evaluated the FDA-approved Roche Cobas AmpliPrep/Cobas TaqMan (CAP/CTM) HIV-1 viral

119 Although Roche COBAS Ampliprep/COBAS TaqMan (CAP/CTM) systems are

120 The Roche Cobas AmpliPrep/Cobas TaqMan CMV test (Cobas CMV)

121 e assessed: the Abbott RealTime HBV IUO, the Roche Cobas AmpliPrep/Cobas TaqMan HBV test, the Roche C

122 nge, the assay is highly correlated with the Roche cobas AmpliPrep/cobas TaqMan HCV Test, version 2.0

123 Two new FDA-approved assays, the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test (RT) and t

124 anti-HIV-1 antibodies), but positive by the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test v2.0 (targ

125 Compared to the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test, the new S

126 The Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test, v2.0 (the

127 results were compared with results from the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 test, v2.0.

128 tima assay was also compared to those of the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 v.2 (CAP/CTM) a

129 mated real-time HIV-1 viral load assays, the Roche Cobas AmpliPrep/Cobas TaqMan test and the Abbott R

130 ots (DPS) with a commonly used VL assay, the Roche Cobas Ampliprep/Cobas TaqMan V.2.0 (CAP/CTM).

131 fied inefficiently with gSCA compared to the Roche Cobas Ampliprep/TaqMan 2.0, whereas all 10 samples

132 iagnostic Medical Devices Directive-approved Roche COBAS AmpliPrep/TaqMan96 real-time PCR assay by co

133 Panel and two commercial automated formats, Roche Cobas and NeuMoDx.

134 een swabs for both viral gene targets in the Roche cobas assay (p=0.05 and p=0.05) as well as the Neu

135 re 96.6% for the Abbott assay, 96.3% for the Roche Cobas assay, 94.5% for the Roche Amplicor assay, 9

136 inflammatory biomarkers were measured using Roche cobas c702 and Meso Scale Discovery V-Plex Plus: h

137 We performed a prospective evaluation of the Roche cobas Liat group A streptococcus (GAS) assay compa

138 se transcription-PCR (RT-PCR) platforms, the Roche Cobas SARS-CoV2 and the Cepheid Xpert Xpress SARS-

139 point was proportion with HBV DNA <69 IU/mL (Roche COBAS Taqman assay; Roche Molecular Systems, Inc,

140 e Cobas AmpliPrep/Cobas TaqMan HBV test, the Roche Cobas TaqMan HBV test with HighPure system, and th

141 urements of HCV RNA were performed using the Roche COBAS TaqMan HCV test and the Abbott RealTime HCV

142 The Roche COBAS TaqMan HCV test for research use only (RUO)

143 We evaluated the Abbott RealTime (ART) and Roche Cobas TaqMan Hepatitis C virus (HCV) viral load as

144 st) and compared results with those of LABT (Roche COBAS TaqMan HIV-1 Qualitative test) with respect

145 V-2 (Cepheid, DiaSorin, Hologic Panther, and Roche Cobas) on a total of 169 nasopharyngeal swabs.

146 ulvovaginal-swab and urine specimens by PCR (Roche Cobas) or strand displacement amplification (SDA;

147 ercial high-throughput laboratory analyzers (Roche Cobas, Abbott m2000, and Hologic Panther Fusion) a

148 tibodies from different vendors (Vector, BD, Roche, Dako, Novocastra, and Accurate) and DNA denaturat

149 24 weeks (polymerase chain reaction, TaqMan, Roche; detection limit 10 IU/mL).

150 NA was quantified by using Amplicor Monitor (Roche Diagnostic Systems, Inc, Branchburg, NJ) from 275

151 -Probe Inc.), the Amplicor CT/NG Assay (PCR; Roche Diagnostics Corp.), or the BD ProbeTec ET System C

152 ghtCycler Strep B analyte-specific reagents (Roche Diagnostics Corporation, Indianapolis, Ind.), were

153 o 36 h after PCI with the Multiplate device (Roche Diagnostics GmbH, Mannheim, Germany).

154 d was extracted using the MagNA Pure system (Roche Diagnostics) and subsequently tested by each PCR m

155 tion capacity was documented by LightCycler (Roche Diagnostics) measurements of virion-associated hep

156 cially available clinical laboratory method (Roche Diagnostics) to measure PTH concentrations with a

157 eared rapid (<20 min) PCR assay (Cobas Liat; Roche Diagnostics) to our routine influenza A and B real

158 the Linear Array HPV genotyping assay (LA) (Roche Diagnostics), INNO-LiPA HPV Genotyping Extra (LiPA

159 energy transfer probes and the LightCycler (Roche Diagnostics), which will detect the presence of th

160 eic acid using the MagNA Pure LC instrument (Roche Diagnostics).

161 standard troponin T and testing for hs-cTnT (Roche Diagnostics, Basel, Switzerland) at presentation.

162 The Amplicor HIV-1 DNA PCR assay (Roche Diagnostics, Branchburg, NJ) requires 500 microl o

163 were sequenced with the 454GS FLX Titanium (Roche Diagnostics, Indianapolis, IN) and GAIIx (Illumina

164 ing and endoxifen measurements by Amplichip (Roche Diagnostics, Indianapolis, IN) and high-performanc

165 ydia trachomatis and N. gonorrhoeae (CT/NG) (Roche Diagnostics, Indianapolis, IN) followed by confirm

166 ed to the TaqMan HCV load ASR assay (TaqMan; Roche Diagnostics, Indianapolis, IN) that targets the 5'

167 Cobas LIAT Influenza A/B assay (LIAT assay; Roche Diagnostics, Indianapolis, IN) to other urgent car

168 al-time PCR analyte-specific reagents (ASR) (Roche Diagnostics, Indianapolis, IN) were also tested by

169 agen, Gaithersburg, MD), the cobas HPV test (Roche Diagnostics, Indianapolis, IN), and the APTIMA HPV

170 ysis probes using the LightCycler platforms (Roche Diagnostics, Indianapolis, IN).

171 using the LINEAR ARRAY HPV Genotyping Test (Roche Diagnostics, Indianapolis, Indiana), which detects

172 as recognized by the Elecsys NTproBNP assay (Roche Diagnostics, Indianapolis, Indiana).

173 cer Association, Lance Armstrong Foundation, Roche Diagnostics, Pfizer, and Novartis.

174 BMS, Pfizer, Boehringer Ingelheim, Roche Diagnostics.

175 hs-cTn was measured with 3 assays (hs-cTnT, Roche Diagnostics; hs-cTnI, Beckman-Coulter; hs-cTnI Sie

176 d B viruses (Alere i [Alere] and cobas Liat [Roche Diagnostics]) with the influenza A and B virus tes

177 otherapeutics, stimulated by the Hoffmann-La Roche discovery that Nutlin-3 can restore apoptosis in c

178 The Basel S-gene and Roche E-gene assays were concordant in 7475 cases (97.5%

179 S-CoV-2, were analyzed in parallel using the Roche Elecsys SARS-CoV-2 total antibody and Abbott Alini

180 s-report) or standard reporting (std-report; Roche Elecys).

181 n be manipulated to give optically pure homo-Roche ester chirons.

182 Roche ester derivatives were converted to trisubstituted

183 ar sequence) from commercially available (R)-Roche ester in >10% overall yields.

184 ic hydrogenation routes to homologues of The Roche ester tend to be restricted to hydrogenations of i

185 es in a single run of the 454 Life Sciences (Roche) FLX sequencer.

186 F Hoffmann-La Roche-Genentech and the Breast Cancer Research Foundatio

187 as those produced by the 454 Life Sciences (Roche) Genome Sequencer, and can scale to large data set

188 Hoffmann-La Roche global drug safety database for the time frame 31

189 ronchial biopsy specimens was sequenced with Roche GS FLX.

190 16S ribosomal RNA was sequenced with Roche GS-FLX (Genome Sequencer-FLX) pyrosequencing.

191 bled and reconstructed from whole genome 454 Roche GS-FLX and Illumina shotgun sequences.

192 rate the utility of HighSSR in comparison to Roche gsAssembler on two Roche 454 GS FLX runs.

193 ncordance in HCV RNA assessments between the Roche High Pure System/Cobas TaqMan and Abbott RealTime

194 sults from samples tested prospectively with Roche High Pure TaqMan HCV 2.0 test (HPS) were compared

195 Human papillomavirus (HPV) was detected by Roche HPV Linear Array at enrollment, and at 6, 12, and

196 The Roche HPV Linear Array Genotype Test detected high-risk

197 ginal swabs were tested for high-risk HPV by Roche HPV Linear Array.

198 rcumcision trial in Rakai, Uganda, using the Roche HPV Linear Array.

199 3 high-sensitivity (hs) cTn assays: hs-cTnT (Roche), hs-cTnI (Siemens), and hs-cTnI (Abbott).

200 ncing technologies (e.g., 454 Life Sciences [Roche], Illumina sequencing [formerly Solexa sequencing]

201 Founded by Roche in 1968, inaugurated in 1971, and closed in 2000,

202 In this article, we present a Roche in-house effort of screening 746 structurally dive

203 he oral MDM2 antagonist idasanutlin (RG7388; Roche) in patients with high-risk PV/ET for whom at leas

204 sured using an Accuchek() active glucometer (Roche Inc.).

205 ive ocular swabs was investigated (Amplicor; Roche, Indianapolis, IN).

206 National Institutes of Health, Genentech, Roche Laboratories, Lilly Research Laboratories, and Pre

207 Quantitative PCR (qPCR) (Roche Light Cycler 480) and ddPCR (Bio-Rad QX100 droplet

208 erence laboratories using two platforms, the Roche LightCycler 480 system and the Applied Biosystems

209 able solely by melt curve analysis using the Roche LightCycler HSV 1/2 analyte-specific reagent real-

210 We compared the performance of the new Roche LightCycler MRSA advanced test to that of the BD G

211 e and have recently been commercialized (eg, Roche LightCycler SeptiFast and T2 Biosystems T2Candida)

212 lder than Phobos' current orbit inside Mars' Roche limit.

213 f HC2-positive results were confirmed by the Roche line blot assay, compared to 77.2% of those at an

214 anal samples, against the reference standard Roche Linear Array (LA).

215 rcumcision trial in Rakai, Uganda, using the Roche Linear Array assay, which detects 37 HPV genotypes

216 s, and HPV genotypes were detected using the Roche Linear Array assay.

217 es, using a polymerase chain reaction assay (Roche Linear Array genotyping assay).

218 ce of L1 sequences using two versions of the Roche Linear Array genotyping assay.

219 and the widely used, commercially available Roche Linear Array genotyping PCR assay.

220 e compared the cobas HPV test (cobas) to the Roche Linear Array HPV genotyping assay (LA) and cytolog

221 A widely used genotyping assay is the Roche Linear Array HPV genotyping test (LA).

222 ical specimens previously evaluated with the Roche Linear Array HPV genotyping test (LA).

223 ere evaluated for 37 HPV genotypes using the Roche LINEAR ARRAY HPV Genotyping Test (Roche Molecular

224 for 36 HPV genotypes was performed using the Roche Linear Array HPV genotyping test.

225 For detection of HPV types, a Roche Linear Array test was performed.

226 cervical samples for HPV DNA detection using Roche Linear Array were collected semiannually for two y

227 ected penile swab sample for HPV genotyping (Roche Linear Array) and completed a demographic and risk

228 9 and PGMY11 L1 primer pools and by use of a Roche linear array.

229 Genital HPV genotypes were detected using Roche Linear Array.

230 F Hoffmann-La Roche Ltd and Genentech Inc.

231 Hoffmann-La Roche Ltd, Basel, Switzerland) versus ranibizumab (Lucen

232 Hoffmann-La Roche Ltd, Genentech, Inc.

233 rawn overview map of metabolism based on the Roche map satisfies (ii) and comes close to satisfying (

234 The 454 GS Junior (Roche), MiSeq (Illumina) and Ion Torrent PGM (Life Techn

235 nc., Des Plaines, IL), the Cobas CT/NG test (Roche Molecular Systems Inc., Alameda, CA), and the BD P

236 ated hrHPV tests, the cobas HPV test (cobas, Roche Molecular Systems) and Hybrid Capture 2 (hc2, Qiag

237 The linear array HPV genotyping test (Roche Molecular Systems) was used as a reference method

238 kinson Co., Sparks, MD), and Amplicor (PCR) (Roche Molecular Systems, Branchburg, NJ).

239 HBV DNA <69 IU/mL (Roche COBAS Taqman assay; Roche Molecular Systems, Inc, Pleasanton, CA).

240 TaqMan is a registered trademark of Roche Molecular Systems, Inc.

241 .), and COBAS TaqMan (COBAS TaqMan HCV Test; Roche Molecular Systems, Inc.) assays.

242 MPLICOR Hepatitis C Virus Test, version 2.0; Roche Molecular Systems, Inc.), and COBAS TaqMan (COBAS

243 Cobas influenza A/B nucleic acid test (LIAT; Roche Molecular Systems, Inc.), and Xpert Xpress Flu (Xp

244 B virus (HBV) analyte-specific reagent (ASR; Roche Molecular Systems, Inc., Branchburg, NJ) is design

245 OBAS AMPLICOR HCV MONITOR Test, version 2.0; Roche Molecular Systems, Inc., Branchburg, NJ), COBAS AM

246 Corp., Gaithersburg, MD), Linear Array (LA; Roche Molecular Systems, Pleasanton, CA), and Amplicor (

247 ular Systems, Pleasanton, CA), and Amplicor (Roche Molecular Systems, Pleasanton, CA).

248 the Roche LINEAR ARRAY HPV Genotyping Test (Roche Molecular Systems, Pleasanton, California), and fa

249 ens were determined using RealTime HIV-1 and Roche Monitor (v1.5).

250 Roche Monitor and Bayer bDNA detected 27 out of 28 and 1

251 for acute HIV infection) was compared with a Roche Monitor HIV RNA polymerase chain reaction assay.

252 che RT-PCR), Roche Amplicor Monitor HCV 2.0 (Roche Monitor), and Bayer VERSANT HCV RNA 3.0 (Bayer bDN

253 After resolving all Roche N. gonorrhoeae-positive results with two additiona

254 reaction assay and hybridization to a custom Roche NimbleGen promoter array.

255 a method for whole-exome sequencing coupling Roche/NimbleGen whole exome arrays to the Illumina DNA s

256 -32) and 2 commercial assays (Triage BNP and Roche NT-proBNP).

257 slet isolations utilizing IPC from VitaCyte, Roche, or SERVA collagenase-protease enzyme mixtures.

258 Roche Pharma AG, Mundipharma, German Federal Ministry of

259 erification process between the end user and Roche Pharmaceuticals, and mandatory destruction of empt

260 oup, under the sponsorship of Genentech Inc, Roche Pharmaceuticals, and OSI Pharmaceuticals, Inc, was

261 rial genes from pooled samples using the 454/Roche platform.

262 scopy: the Hybrid Capture 2 (Qiagen), Cobas (Roche), PreTect HPV-Proofer (NorChip), Aptima HPV (Gen-P

263 Roche Products Ltd (educational grant), supported by Nat

264 meras using a nSSU data set derived from 454 Roche pyrosequencing of replicated, large control pools

265 udinal and cross-sectional samples using 454/Roche pyrosequencing, in total analyzing 174,185 sequenc

266 ethods were prospectively employed to impact Roche research projects, with the aim of highlighting th

267 Discrepant results were tested using the Roche reverse line blot (RLB) or Linear Array (LA) assay

268 ent with clinician-obtained brushes when the Roche Reverse Line Blot Assay (RLBA) was used (for swabs

269 HPV types were determined by the Roche Reverse Linear Array HPV genotyping assay.

270 The Roche RT-PCR assay gave mean viral load values that were

271 the mean viral load value obtained with the Roche RT-PCR assay was, on average, 0.15 log10 lower tha

272 nsitivity and linear range of the Abbott and Roche RT-PCR assays enable them to be used for HCV diagn

273 tested in the Bayer bDNA, Abbott RT-PCR, and Roche RT-PCR assays.

274 Abbott RT-PCR and Roche RT-PCR detected all 28 replicates with a concentra

275 anscription-PCR [RT-PCR]), Roche TaqMan RUO (Roche RT-PCR), Roche Amplicor Monitor HCV 2.0 (Roche Mon

276 Good correlation was obtained for the Roche RUO-MPLC and Abbott ASR-Q (R(2) = 0.84 and R(2) =

277 Our study demonstrates that Roche RUO-MPLC and Abbott ASR-Q provided acceptable resu

278 s processed on the MagNA Pure LC instrument (Roche RUO-MPLC) and Abbott analyte-specific reagents (AS

279 national units (IU) of IFN-alpha (Roferon-A; Roche s.p.a., Milano, Italy) subconjunctivally inside th

280 ogies such as Illumina's Solexa platform and Roche's 454 approach provide new avenues for investigati

281 ate performance on control data sequenced on Roche's 454 platform, and compare the results to the mos

282 led proportions were shotgun-sequenced using Roche's 454 sequencing platform.

283 ercial next-generation sequencing platforms: Roche's 454, Illumina's Solexa and Applied Biosystems' S

284 Collagenase from Roche, Serva/Nordmark (Uetersen, Germany), and VitaCyte

285 We included all published and unpublished Roche-sponsored randomised placebo-controlled, double-bl

286 orm and compared the results to those of the Roche TaqMan Analyte-Specific Reagent (TaqMan) and Bayer

287 1 test on the m2000 system (Abbott), and the Roche TaqMan HIV-1 test, v2.0 (TaqMan).

288 (Abbott reverse transcription-PCR [RT-PCR]), Roche TaqMan RUO (Roche RT-PCR), Roche Amplicor Monitor

289 VL was measured by Roche TaqMan.

290 apid virologic response (mRVR; VL <25 IU/mL [Roche TaqMan] at week 4 and undetectable at weeks 8 to 2

291 to 98.3%), respectively, compared to to the Roche test.

292 The finding by scientists at Hoffmann-La Roche that cis-imidazolines could disrupt the protein-pr

293 itative agreement between the Abbott IgG and Roche total antibody assays was 98.7% (658/667), with Co

294 pre-COVID-19 samples for the Abbott IgG and Roche total antibody assays were 99.65% (95% CI, 98.72 t

295 nucleocapsid antibody tests (Abbott IgG and Roche total antibody) and one spike protein antibody tes

296 92.7% (51/55, Abbott IgG) and 85.5% (47/55, Roche total antibody).

297 22 (43.1%) were reactive by the Abbott IgG, Roche total antibody, and Abbott IgM assays, respectivel

298 or diluted using the Amplicor HIV-1 DNA PCR (Roche), version 1.5.

299 ded sequencing using the GS20 Sequencer (454/Roche), we found that over 99.8% of obtained sequences c

300 To make this approach feasible, Roche would have to provide additional lysis buffer and